- Home
- HRMY vs COCO Comparison
HRMY vs COCO Comparison
Compare HRMY & COCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- COCO
- Stock Information
- Founded
- HRMY 2017
- COCO 2004
- Country
- HRMY United States
- COCO United States
- Employees
- HRMY N/A
- COCO N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- COCO Beverages (Production/Distribution)
- Sector
- HRMY Health Care
- COCO Consumer Staples
- Exchange
- HRMY Nasdaq
- COCO Nasdaq
- Market Cap
- HRMY 1.6B
- COCO 1.8B
- IPO Year
- HRMY 2020
- COCO 2021
- Fundamental
- Price
- HRMY $34.05
- COCO $33.31
- Analyst Decision
- HRMY Strong Buy
- COCO Buy
- Analyst Count
- HRMY 8
- COCO 7
- Target Price
- HRMY $52.88
- COCO $35.57
- AVG Volume (30 Days)
- HRMY 701.6K
- COCO 744.3K
- Earning Date
- HRMY 05-06-2025
- COCO 04-30-2025
- Dividend Yield
- HRMY N/A
- COCO N/A
- EPS Growth
- HRMY 13.13
- COCO 11.36
- EPS
- HRMY 2.62
- COCO 1.01
- Revenue
- HRMY $744,852,000.00
- COCO $535,236,000.00
- Revenue This Year
- HRMY $20.06
- COCO $12.42
- Revenue Next Year
- HRMY $18.40
- COCO $10.73
- P/E Ratio
- HRMY $13.10
- COCO $32.89
- Revenue Growth
- HRMY 20.62
- COCO 8.01
- 52 Week Low
- HRMY $26.47
- COCO $23.56
- 52 Week High
- HRMY $41.61
- COCO $40.32
- Technical
- Relative Strength Index (RSI)
- HRMY 69.53
- COCO 52.86
- Support Level
- HRMY $29.82
- COCO $29.74
- Resistance Level
- HRMY $30.61
- COCO $35.70
- Average True Range (ATR)
- HRMY 1.12
- COCO 1.64
- MACD
- HRMY 0.74
- COCO 0.40
- Stochastic Oscillator
- HRMY 92.78
- COCO 59.90
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About COCO The Vita Coco Company Inc.
The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. The company has two segments: The Americas segment which comprises of operations in the U.S. and Canada; and The International segment that comprises of operations in Europe, the Middle East, Africa and the Asia Pacific regions. The Americas segment derives maximum revenue. Geographical presence of the company is in United States, United Kingdom and All other countries.